| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.eris.co.in | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 10,191.12 Cr. | |
| Earnings per share (EPS) | 27.44 | Trailing Twelve Months Ending 2021-06 |
| Price-Earning Ratio (PE) | 27.34 | Trailing Twelve Months Ending 2021-06 |
| Industry PE | 32.74 | Trailing Twelve Months Ending 2021-06 |
| Book Value / Share | 124.16 | Trailing Twelve Months Ending 2021-06 |
| Price to Book Value | 6.04 | Calculated using Price: 750.10 |
| Dividend Yield | 0.73 | Period Ending 2021-03 |
| No. of Shares Subscribed | 13.59 Cr. | 135,863,494 Shares |
| FaceValue | 1 | |
| Company Profile | ||
|
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market. The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers. The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists. Business area of the company The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders. History and milestones
|
||
Company Profile
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.
The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.
The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.
Business area of the company
The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.
History and milestones
| 1 Day |
|
-0.62% |
| 1 Week |
|
-2.82% |
| 1 Month |
|
+1.38% |
| 3 Month |
|
+25.42% |
| 6 Month |
|
+29.54% |
| 1 Year |
|
+38.61% |
| 2 Year |
|
+83.80% |
| 5 Year |
|
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 77.39 | 75.91 | 50.12 | 40.30 | 47.68 | 56.90 | 41.30 | 28.96 | 24.28 | |
| Return on Capital Employed (%) | 107.17 | 103.88 | 68.93 | 49.25 | 54.56 | 62.56 | 35.76 | 26.54 | 25.44 | |
| Return on Assets (%) | 36.38 | 42.75 | 32.09 | 28.59 | 36.17 | 43.89 | 27.31 | 20.02 | 20.33 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 48 | 106 | 177 | 266 | 300 | 567 | 861 | 1,151 | 1,296 | |
| Non Curr. Liab. | 14 | 17 | 18 | 19 | 20 | 12 | 248 | -66 | -80 | |
| Curr. Liab. | 35 | 44 | 71 | 65 | 69 | 129 | 294 | 377 | 220 | |
| Minority Int. | 5 | 5 | 4 | 4 | 3 | 24 | 25 | 18 | ||
| Equity & Liab. | 102 | 172 | 270 | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | |
| Non Curr. Assets | 33 | 45 | 115 | 191 | 169 | 463 | 1,061 | 827 | 902 | |
| Curr. Assets | 69 | 126 | 155 | 163 | 222 | 270 | 367 | 653 | 535 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 102 | 172 | 270 | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 274 | 393 | 509 | 546 | 597 | 750 | 856 | 982 | 1,074 | |
| Other Income | 1 | 1 | 4 | 3 | 3 | 25 | 26 | 32 | 16 | |
| Total Income | 275 | 395 | 513 | 549 | 600 | 775 | 882 | 1,014 | 1,090 | |
| Total Expenditure | -215 | -307 | -410 | -424 | -425 | -480 | -533 | -637 | -706 | |
| PBIDT | 60 | 87 | 103 | 125 | 175 | 294 | 349 | 377 | 384 | |
| Interest | -1 | -1 | 0 | 0 | 0 | -1 | -11 | -23 | -2 | |
| Depreciation | -3 | -3 | -5 | -16 | -20 | -23 | -26 | -36 | -50 | |
| Taxation | -18 | -25 | -27 | -20 | -20 | -24 | -17 | -26 | -35 | |
| Exceptional Items | ||||||||||
| PAT | 37 | 58 | 71 | 89 | 135 | 247 | 295 | 291 | 297 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 30 | 38 | 90 | 90 | 131 | 200 | 235 | 223 | 271 | |
| Cash Fr. Inv. | -19 | -36 | -83 | -92 | -44 | -184 | -590 | -5 | 123 | |
| Cash Fr. Finan. | -10 | -3 | -2 | 0 | -84 | -24 | 363 | -221 | -335 | |
| Net Change | 1 | -1 | 5 | -2 | 4 | -8 | 8 | -3 | 60 | |
| Cash & Cash Eqvt | 3 | 2 | 7 | 5 | 9 | 2 | 11 | 8 | 67 |
|
Thu, 05 Aug 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING |
|
Thu, 05 Aug 2021
INTIMATION OF SUBMISSION OF APPLICATION FOR RECLASSIFICATION Pursuant to application received by the Company on February 18 2021 regarding the request for reclassification of Promoter from Promoter category to Public category and the approvals for the same obtained from the Board of Directors and shareholders of the Company we wish to inform you that the Company has made an application to BSE Limited and National Stock Exchange of India Limited for re-classification of the following persons from the Promoter and Promoter Group category to the Public category of shareholders of the Company in accordance with Regulation 31A of the Listing Regulations. |
|
Wed, 04 Aug 2021
NOTICE OF BOOK CLOSURE In accordance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Register of Members and Share Transfer Books of the Company will be closed on Wednesday August 25 2021 for the purpose of Fifteenth Annual General Meeting of the Company scheduled to be held on Wednesday September 01 2021. |
| Wed, 04 Aug 2021 |
Closing Below Previous Low
|
Close Within 52 Week High Zone
|
Close Crossing 20 EMA From Above
|
CCI Trending Down
|
ROC Trending Down
|
Equities
M.F.
Sectors